Étiquette : Rheumatology

PK MED

by jbertholdin Biotech, Pharma

PK MED

About the company

PK MED is a French innovative biotech company, privately owned and established in 2019 with the support of Truffle Capital, a prominent European Venture Capital firm specializing in Life sciences.

​PK MED specializes in the innovative development of custom-designed, injectable, and biodegradable micro-implants. Their expertise spans across critical healthcare domains, focusing on local drug delivery systems for rheumatology (PKM-01) and enhancing cell-homing techniques to improve bone marrow transplantation outcomes (PKM-02).

About the solution

Lead product candidate PKM-01 is developed to treat gout, an excruciating and increasingly prevalent form of arthritis. Today, approved products take time to partially alleviate pain and come with real safety risks.
PKM-01 is a drug combination product (sustained release formulation of the anti-inflammatory drug, colchicine, and an anesthetic) to be injected in the effected joint. PKM-01 is designed to be a new treatment paradigm in gout flares – a safe and very effective pain killer providing relief within minutes.

Website
Key information

–  Therapeutic areas: Rheumatology, Bone marrow transplantation

–  Based in: Headquarter : Paris (FRANCE) R&D : Lyon (FRANCE)

–  Employees: 1-10

–  Created in: 2019

CLINSEARCH

by jbertholdin Institutions, Service Providers & others

CLINSEARCH

About the company

ClinSearch is a full service European CRO, established in 1999, offering clinical research and medical evaluation services throughout Europe, as well as the Middle East and the United States.

They have conducted hundreds of studies, from phase I to IV studies, early access programs, post-marketing studies, RWE, PASS, PAES, database analyses and medico-economic studies, involving 1 patient up to 220,000 subjects.
Their customers include global and local medical device, biotechnology and pharmaceutical companies, as well as public health institutions.

About the solution

Full service offering from A to Z: methodological input to study design through to peer-reviewed publications, passing via in-house development of sophisticated healthcare tools (EDC, ePRO, …).

The in-house team of over 70 people work from our headquarters in Malakoff (France), but hail from ~15 different countries and speak over 10 languages, and are trained to a high standard (MD, PhD, PharmD, MS, MPH …).

Website
Key information

–  Therapeutic areas: Addiction, Aesthetics, Algorithm, Software, Cardiovascular, Dermatology, Fertility, Immunology, Infectiology, Hematology, Neurology, Neuromuscular, Neurovascular, Nursing care, Orthopedic, Oncology, Rheumatology, Rare diseases, Respiratory, Surgery, Urology

–  Based in: Boston (USA)

–  Employees: 51-200

–  Created in: 1999

HTL BIOTECHNOLOGY

by jbertholdin Biotech, Pharma

HTL BIOTECHNOLOGY

About the company

HTL Biotechnology is a French biotech company and world leader in the development and responsible bioproduction of pharmaceutical-grade biopolymers. These biopolymers are used by healthcare companies for the development of treatments in a wide range of leading therapeutic areas such as ophthalmology, dermatology, medical aesthetics, and rheumatology.

For over 30 years, HTL Biotechnology has been a driving force for innovation in the sector, collaborating with research entities and biotech companies to address tomorrow’s medical needs (regenerative medicine, drug delivery, etc.). HTL Biotechnology is a fast-growing international company, exporting nearly 80% of its production to over 30 countries. To meet these growing global needs for biopolymers, HTL Biotechnology has also established subsidiaries in Singapore and the United States, including the construction of a production unit for a neuromodulator. Historically based in Javené (Brittany), the company consolidates production, innovation, research and development, and quality activities on-site. HTL Biotechnology employs nearly 300 collaborators worldwide.

About the solution

Biopolymers are at the heart of today’s and tomorrow’s therapeutic innovations, HTL Biotechnology offers:

Today’s portfolio: pharmaceutical-grade hyaluronic acid, PN & PDRN, cosmetic-grade sodium DNA

Quality is essential, and HTL guarantees that all its products comply with the highest quality standards and good manufacturing practices (GMP-compliant). Our commitment to safety and excellence is proven: no batch recalls in three decades, auditing and certification by regulatory bodies such as the FDA (USA). – Innovation portfolio: heparosan, oligo-HA – Biopolymer platform service: HTL offers expert advice and support to companies wishing to embark on the industrial production of a modified hyaluronic acid compound.

Website
Key information

–  Therapeutic areas: Ophthalmology, Dermatology, Medical Aesthetics, Rheumatology

–  Based in: Javené (FRANCE) Subsidiary : HTL BMI based in Massachusetts (US)

–  Employees: 201 – 500

– Created in: 1992